Collegium Pharmaceutical competitors

Collegium Pharmaceutical Competitors include Assertio Therapeutics, Cesca Therapeutics, Celldex Therapeutics and Synthetic Biologics.
Add company...
Collegium Pharmaceutical
Collegium Pharmaceutical
Collegium Pharmaceutical is a specialty pharmaceutical company focused on the development of products for the treatment of chronic pain.
Assertio Therapeutics
Assertio Therapeutics
Assertio Therapeutics (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other.
Cesca Therapeutics
Cesca Therapeutics
Cesca Therapeutics is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine.
Celldex Therapeutics
Celldex Therapeutics
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.
Synthetic Biologics
Synthetic Biologics
Synthetic Biologics is a late-stage clinical company developing therapeutics designed to preserve the microbiome.
Founding Date
Founding Date
2002
Founding Date
1995
Founding Date
1986
Founding Date
1983
Founding Date
2001
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Canton, US HQ
Locations
Newark, US HQ
Locations
Rancho Cordova, US HQ
Wuxi Shi, CN
Locations
Hampton, US HQ
Needham, US
Fall River, US
Branford, US
Locations
Rockville, US HQ
Employees
Employees
2507% increase
Employees
43411% decrease
Employees
95
Employees
1926% decrease
Employees
2414% decrease
Valuation ($)
Valuation ($)
524 m
Valuation ($)
267.3 m
Valuation ($)
6.7 m
Valuation ($)
49.8 m
Valuation ($)
276.8 k
Twitter followers
Twitter followers
N/A
Twitter followers
N/A
Twitter followers
351
Twitter followers
N/A
Twitter followers
1.3 k

Financial

Revenue (est.)
Revenue (est.)
N/A
Revenue (est.)
$380.7m (FY, 2017)
Revenue (est.)
$14.5m (FY, 2017)
Revenue (est.)
$12.7m (FY, 2017)
Revenue (est.)
N/A
Cost of goods
Cost of goods
N/A
Cost of goods
$72.6m (FY, 2017)
Cost of goods
$8.7m (FY, 2017)
Cost of goods
N/A
Cost of goods
N/A
Gross profit
Gross profit
N/A
Gross profit
$308.1m (FY, 2017)
Gross profit
$5.8m (FY, 2017)
Gross profit
N/A
Gross profit
N/A
Net income
Net income
($74.9m) (FY, 2017)
Net income
($102.5m) (FY, 2017)
Net income
($29.1m) (FY, 2017)
Net income
($93m) (FY, 2017)
Net income
($15.5m) (FY, 2017)

Operating

Patents Issued
Patents Issued
N/A
Patents Issued
N/A
Patents Issued
25 (FY, 2016)
Patents Issued
300 (FY, 2016)
Patents Issued
N/A

Funding

Total funding raised
Total funding raised
$ 106m
Total funding raised
$ 875m
Total funding raised
$ 15m
Total funding raised
$ 2m
Total funding raised
$ 16.1m
For sources of this data, please see the company profileDownload Excel

View company profiles

Assertio Therapeutics
HQ
Newark, US
Employees
434↓ 11% decrease

Assertio Therapeutics (formerly Depomed) is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other.

View company
Cesca Therapeutics
HQ
Rancho Cordova, US
Employees
95

Cesca Therapeutics is engaged in the research, development, and commercialization of cell-based therapeutics for use in regenerative medicine.

View company
Celldex Therapeutics
HQ
Hampton, US
Employees
192↓ 6% decrease

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate.

View company
Synthetic Biologics
HQ
Rockville, US
Employees
24↓ 14% decrease

Synthetic Biologics is a late-stage clinical company developing therapeutics designed to preserve the microbiome.

View company